Six-Year Rate of Visual Field Progression in the Laser in Glaucoma and Ocular Hypertension Trial.
Montesano Giovanni, Crabb David P, Garway-Heath David F, Wright David M, Konstantakopoulou Evgenia, Nathwani Neil, Ometto Giovanni, Gazzard Gus
AI Summary
First-line SLT better preserved visual fields over six years than drops in glaucoma/OHT patients. SLT should be preferred as initial treatment.
Abstract
Purpose
To compare the 6-year rate of visual field (VF) progression in the 2 arms of the Laser in Ocular Hypertension and Glaucoma Trial (LiGHT), comparing selective laser trabeculoplasty (SLT) and drops as first treatment in ocular hypertension (OHT) and open-angle glaucoma (OAG).
Design
Post hoc analysis of data from randomized clinical trial.
Participants
Patients with newly diagnosed OHT/OAG recruited in the LiGHT trial.
Methods
In each patient, we selected the better (baseline mean deviation [MD]) eligible eye with at least 3 reliable VFs (false-positive errors < 15%) over at least 6 months. We estimated the rate of MD progression using a published hierarchical linear mixed effect model (LMM), designed to increase precision by minimizing the effect of perimetric learning and test-retest noise. Secondary analyses were performed to assess the differences in rate across baseline severity groups (OHT, mild OAG, and moderate/severe OAG); the effect of glaucoma surgery and switch to SLT in the drops-first arm, by truncating the VF series; and the effect of cataract and cataract surgery, by using the mean pattern deviation (MPD) instead of the MD.
Main outcome measure: Mean difference in the rate of VF MD progression between patients in the SLT-first arm and drops-first arm.
Results
Data from 710 eyes (482 with OAG and 354 in the SLT-first arm) were analyzed. The 2 arms had similar baseline MD (P = 0.7). The average intraocular pressure (IOP) during follow-up was 16.1 [14.2-18.2] for the drops-first arm and 16.8 [14.6-18.6] in the SLT-first arm (median [interquartile range], P = 0.057). The mean [95% credible interval] MD rate was -0.37 [-0.43 to -0.31] decibels (dB)/year in the drops-first arm and -0.26 [-0.31 to -0.21] dB/year in the SLT-first arm (P = 0.007). When stratified by severity, this difference was significant only in mild OAG (P = 0.035, the largest sub-group). The secondary analyses largely confirmed the main results. The difference in MPD rate was also significantly slower in the SLT-first arm (P < 0.001).
Conclusions
First-line SLT was more effective than drops at preserving VF. Selective laser trabeculoplasty should be preferred as the first line of treatment in newly diagnosed OHT and OAG eyes.
Financial disclosure(s): Proprietary or commercial disclosure may be found after the references.
MeSH Terms
Shields Classification
Key Concepts4
First-line selective laser trabeculoplasty (SLT) was more effective than drops at preserving visual field (VF) in newly diagnosed ocular hypertension (OHT) and open-angle glaucoma (OAG) eyes, with a mean visual field mean deviation (MD) rate of -0.26 [-0.31 to -0.21] decibels (dB)/year in the SLT-first arm compared to -0.37 [-0.43 to -0.31] dB/year in the drops-first arm (P = 0.007).
The difference in visual field mean deviation (MD) rate between first-line selective laser trabeculoplasty (SLT) and drops was significant only in mild open-angle glaucoma (OAG) (P = 0.035), which was the largest subgroup, in newly diagnosed ocular hypertension (OHT) and open-angle glaucoma (OAG) eyes.
The mean pattern deviation (MPD) rate was significantly slower in the selective laser trabeculoplasty (SLT)-first arm compared to the drops-first arm (P < 0.001) in newly diagnosed ocular hypertension (OHT) and open-angle glaucoma (OAG) eyes.
The average intraocular pressure (IOP) during follow-up was 16.1 [14.2-18.2] mmHg in the drops-first arm and 16.8 [14.6-18.6] mmHg in the selective laser trabeculoplasty (SLT)-first arm (median [interquartile range], P = 0.057) in newly diagnosed ocular hypertension (OHT) and open-angle glaucoma (OAG) eyes.
Related Articles5
Editorial to: visual field after anti-vascular endothelial growth factor therapy and laser treatment for retinopathy of prematurity.
EditorialVisual Field Changes in Diabetic Retinopathy: Natural History and after Pan-Retinal Photocoagulation in the Diabetic Retinopathy Study and the ETDRS.
Cohort StudyThe Glaucoma Intensive Treatment Study (GITS): A Randomized Controlled Trial Comparing Intensive and Standard Treatment on 5 Years Visual Field Development.
Randomized Controlled TrialVisual Field Outcomes from the Multicenter, Randomized Controlled Laser in Glaucoma and Ocular Hypertension Trial (LiGHT).
Randomized Controlled TrialThe effect of treatment on progression of glaucoma.
Clinical TrialIs this article assigned to the wrong chapter(s)? Let us know.